ENTITY
Sino Biopharmaceutical

Sino Biopharmaceutical (1177 HK)

168
Analysis
Health CareHong Kong
Sino Biopharmaceutical Limited, through its subsidiaries, researches, develops, produces, and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis.
more
Refresh
16 Jul 2024 01:34

China Traditional Chinese Medicine (570 HK): Update Provides Fodder for Bulls and Bears

It is rare for the market to misprice an HKEx merger arb to this extent, suggesting something is amiss. Nevertheless, the risk (10.6% downside) vs...

Logo
355 Views
Share
07 Apr 2024 14:06

China Healthcare Weekly (Apr.6) - Boom of TCM Injections Is Coming, Defects in GLP-1s, Sino Biopharm

Payment policy relaxation will drive rapid sales growth of TCM injection.GLP-1 has defects-patients will lose not only fat but also muscle. Mr...

Logo
393 Views
Share
09 Oct 2023 08:55

China's Weight Loss Drug Market – The Investment Opportunities and the Risks Behind

The GLP-1 target has been recognized as a blockbuster target, which has attracted great enthusiasm from investors.We analyzed related investment...

Logo
380 Views
Share
25 Feb 2022 06:15

Greater China Funds: China Health Care Reversal

Greater China managers have actively rebalanced portfolios away from China & HK Health Care over the last 6-months, with Taiwan Tech the key...

Logo
335 Views
Share
bearishSenseTime Group
02 Jul 2024 05:50

HSCEI Index Rebalance Preview: Two Changes Likely in September

We forecast two changes in September with a 1-way turnover of 1.8% resulting in a 1-way trade of HK$950m. There will be 1-2 days of ADV to trade on...

Logo
383 Views
Share
x